In vitro bioactivation of 3-(N-phenylamino)propane-1,2-diol by human and rat liver microsomes and recombinant P450 enzymes. Implications for toxic oil syndrome

Chemical Research in Toxicology

Volumn 20, Issue 8, 2007, Pages 1218-1224

  Martínez Cabot, Anna ^a   Morató, Anna ^a   Commandeur, Jan N M ^b   Vermeulen, Nico P E ^b   Messeguer, Angel ^a  

^a DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 (N PHENYLAMINO)PROPANE 1,2 DIOL; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C18; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; PHENOL; PROPANE; UNCLASSIFIED DRUG;

ARTICLE; AUTOOXIDATION; CATALYSIS; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HYDROXYLATION; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; METABOLITE; NONHUMAN; TOXIC OIL SYNDROME;

ANIMALS; BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FOOD CONTAMINATION; FOOD POISONING; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; PLANT OILS; PROPYLENE GLYCOLS; QUINONES; RATS; RECOMBINANT PROTEINS; SPAIN; SUBSTRATE SPECIFICITY; TIME FACTORS;

RATTUS;

EID: 34548516436     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700209p     Document Type: Article

References (35)

1. Grandjean, P., and Tarkowski, S. (1984) Toxic oil syndrome: Mass food poisoning in Spain. Report of a WHO Meeting: Madrid, 21-25 March, 1983, p 21, Copenhaguen, Denmark.
2. Tabuenca, J. M. (1981) Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2, 567.
3. Aldridge, W. N. (1992) The toxic oil syndrome (TOS, 1981): From the disease towards a toxicological understanding of its chemical etiology and mechanism. Toxicol. Lett. 64-65, 59-70.
4. Vazquez Roncero, A., Janer del Valle, C., Maestro Duran, R., and Graciani Constante, E. (1983) New aniline derivatives in cooking oils associated with toxic oil syndrome. Lancet 2, 1024-1025.
5. Closa, D., Folch, E., Calaf, R., Abián, J., Roselló- Catafau, J., and Gelpí, E. (2001) Absortion and effects of 3-(N-phenylamino)-1,2-propanediol esters in relation to toxic oil syndrome. Lipids 36, 1125-1133.
6. Morató, A., Martínez-Cabot, A., Escabrós, J., Bujons, J., and Messeguer, A. (2004) Studies on the toxic oil syndrome: Stereoselective hydrolysis of 3-(phenylamino)propane-1,2-diol esters by human pancreatic lipase. Chem. Res. Toxicol. 17, 889-895.
7. Kilbourne, E. M., Rigau-Perez, J. G., Heath, C. W., Zack, M. M., Falk, H., Martin-Marcos, M., and de Carlos, A. (1983) Clinical epidemiology of toxic oil syndrome. Manifestations of a new illness. N. Engl. J. Med. 309, 1408-1414.
8. Rigau-Perez, J. G., Pérez-Alvarez, L., Dueñas-Castro, S., Choi, K., Thacker, S. B., Germain, J. L., González-de-Andrés, G., Canada-Royo, L., and Pérez-Gallardo, F. (1984) Epidemiologic investigation of an oil-associated pneumonic paralytic eosinophilic syndrome in Spain. Am. J. Epidemiol. 119, 250-260.
9. Lahoz, C., Rose, N. R., and Robinson, C. J. G. (1992) Immunology in Toxic Oil Syndrome: Current knowledge and future perspectives, pp 143-152, World Health Organization, Copenhagen.
10. Gallardo, S., del Pozo, V., Cardaba, B., de Andres, B., Martin-Orozco, E., Fernandez, J. C., Ramón, P., Posada, M., Abaitua, I., and Palomino, P. (1994) Immunological basis of toxic oil syndrome (TOS). Toxicology 93, 289-299.
11. del Pozo, V., de Andres, B., Gallardo, S., Cardaba, B., de Arruda-Chaves, E., Cortegano, M. I., Jurado, A., Palomino, P., Oliva, H., Aguilera, B., Posada, M., and Lahoz, C. (1997) Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: A TH2 immunological mechanism. Toxicology 118, 61-70.
12. Ladona, M. G., Izquierdo-Martinez, M., Posada de la Paz, M., de la Torre, R., Ampurdanes, C., Segura, J., and Sanz, E. J. (2001) Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish Toxic Oil Syndrome. Environ. Health Perspect. 109, 369-375.
13. Ladona, M. G., Bujons, J., Messeguer, A., Ampurdanés, C., Morató, A., and Corbella, J. (1999) Biotransformation and clearance of 3-(phenylamino)propane-1,2-diol, a compound present in samples related to Toxic Oil Syndrome, in C57BL/6 and A/J mice. Chem. Res. Toxicol. 12, 1127-1137.
14. Bujons, J., Ladona, M. G., Messeguer, A., Morató, A., and Ampurdanés, C. (2001) Metabolism of (R)- and (S)-3(phenylamino) propane-1,2-diol in C57BL/6- and A/J-strain mice. Identification of new metabolites with toxicological significance to the toxic oil syndrome. Chem. Res. Toxicol. 14, 1097-1106.
15. Martínez-Cabot, A., Morató, A., and Messeguer, A. (2005) Synthesis and stability studies of the glutathione and N-acetylcysteine adducts of an quinoneimine reactive intermediate generated in the biotransformation of 3-(N-phenylamino)propane-1,2-diol: Implications for toxic oil syndrome. Chem. Res. Toxicol. 18, 1721-1728.
16. Monks, T. J., and Lau, S. S. (1998) The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu. Rev. Pharmacol. Toxicol. 38, 229-255.
17. Weber, T. J., Huang, Q., Monks, T. J., and Lau, S. S. (2001) Differential regulation of redox responsive transcription factors by the nephrocarcinogen 2,3,5-tris(glutathion-5-yl)hydroquinone. Chem. Res. Toxicol. 14, 814-821.
18. Awad, H. M., Boersma, M. G., Boeren, S., Van Bladeren, P. J., Vervoort, J., and Rietjens, I. M. (2003) Quenching of quercetin quinone/quinone methides by different thiolate scavengers: Stability and reversibility of conjugate formation. Chem. Res. Toxicol. 16, 822-831.
19. Carvalho, M., Milhazes, N., Remiao, F., Fernandes, E., Amado, F., Monks, T. J., Carvalho, F., and Bastos, M. L. (2004) Hepatotoxicity of 3,4-methylenedioxyamphetamine and α-methyldopamine in isolated rat hepatocytes: Formation of glutathione conjugates. Arch. Toxicol. 78, 16-24.
20. Jones, D. C., Duvauchelle, C., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., and Monks, T. J. (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313, 422-431.
21. Ferrer, M., Galceran, M., Sanchez-Baeza, F., Casas, J., and Messeguer, A. (1993) Synthesis of aniline derivatives with potential toxicological implications to the Spanish toxic oil syndrome. Liebigs Ann. Chem. 5, 507-511.
22. http://www.fda.gov/cder/drug/drugInteractions/tableSubstrates.htm.
23. http://www.invitrotech.com/filelib/ps_invitrosomes_samplekit.pdf.
24. Venkatakrishnan, K., Von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., and Greenblatt, D. J. (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of acessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28, 1493-1504.
25. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
26. Guengerich, F. P. (2003) Cytochromes P450, drugs, and diseases. Mol. Interventions 3, 194-204.
27. Chang, T. K. H., Gonzalez, F. J., and Waxman, D. J. (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442.
28. Raunio, H., Hakkola, J., Hukkanen, J., Lassila, A., Paivarinta, K., Pelkonen, O., Anttila, S., Piipari, R., Boobis, A., and Edwards, R. J. (1999) Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp. Toxicol. Pathol. 51, 412-417.
29. Mace, K., Bowman, E. D., Vautravers, P., Shields, P. G., Harris, C. C., and Pfeifer, A. M. (1998) Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer 34, 914-920.
30. Hukkanen, J., Pelkonen, O., Hakkola, J., and Raunio, H. (2002) Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32, 391-411.
31. Bernauer, U., Heinrich-Hirsch, B., Tonnies, M., Peter-Matthias, W., and Gundert-Remy, U. (2006) Characterization of the xenobiotic-metabolizing cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol. Lett. 164, 278-288.
32. Castell, J. V., Donato, M. T., and Gomez-Lechon, M. J. (2005) Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp. Toxicol. Pathol. 57, 89-204.
33. Posada de la Paz, M., Phile, R. M., and Abaitua, I. (2001) Toxic Oil Syndrome: The perspective after twenty years. Epidemiol. Rev. 23, 231-247.
34. Silvestri, L., Sonzogni, L., De Silvestri, A., Gritti, C., Foti, L., Zavaglia, C., Leveri, M., Cividini, A., Mondelli, M. U., Civardi, E., and Silini, E. M. (2003) CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int. J. Cancer 104, 310-327.
35. Nagata, K., and Yamazoe, Y. (2002) Genetic polymorphism. Drug Metab. Pharmacokinet. 17, 167-189.